Credit Suisse Sticks to Its Hold Rating for Eli Lilly & Co

Credit Suisse analyst Vamil Divan maintained a Hold rating on Eli Lilly & Co (NYSE: LLY) yesterday and set a price target of $82. The company’s shares closed yesterday at $82.21.

According to TipRanks.com, Divan has 0 stars on 0-5 star ranking scale with an average return of -2.5% and a 42.8% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Portola Pharma.

Currently, the analyst consensus on Eli Lilly & Co is Moderate Buy and the average price target is $91.20, representing a 10.9% upside.

In a report issued on May 10, BMO Capital also maintained a Hold rating on the stock with a $78 price target.

See today’s analyst top recommended stocks >>

Based on Eli Lilly & Co’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.7 billion and net profit of $1.22 billion. In comparison, last year the company had a GAAP net loss of $111 million.

Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health.